Published in Eur J Clin Pharmacol on July 09, 2015
Unlicensed and off label drug use in paediatric wards: prospective study. BMJ (1998) 8.74
Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ (2000) 8.10
Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr (1999) 6.43
Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed (1999) 5.04
Use of "off-label" and unlicensed drugs in paediatric intensive care unit. Lancet (1996) 4.89
Unlicensed and off label prescription of drugs to children: population based cohort study. BMJ (2002) 2.34
Unlicensed and off label drug use by children in the community: cross sectional study. BMJ (2002) 2.30
Off-label use of drugs in neonatal intensive care units. Indian Pediatr (2014) 2.03
Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med (2012) 1.78
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol (2003) 1.50
Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther (2009) 1.47
Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. J Clin Pharm Ther (2011) 1.02
Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. Br J Clin Pharmacol (2014) 1.00
Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics. Eur J Pediatr (2009) 0.98
Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme. Intern Med J (2012) 0.90
Prospective data collection of off-label use of rituximab in Australian public hospitals. Intern Med J (2013) 0.87
Off-label prescribing in palliative care: a survey of independent prescribers. Palliat Med (2012) 0.87
Poor formulation information in published pediatric drug trials. Pediatrics (2005) 0.86
A one-day survey of characteristics of off-label hospital prescription of psychotropic drugs. Pharmacopsychiatry (2007) 0.84
Outcomes of off-label drug uses in hospitals: a multicentric prospective study. Eur J Clin Pharmacol (2014) 0.81
Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag (2014) 0.80
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med (2006) 3.38
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol (2007) 2.73
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet (2004) 2.60
Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab (2007) 2.51
Corneal confocal microscopy: a novel noninvasive means to diagnose neuropathy in patients with Fabry disease. Muscle Nerve (2009) 1.51
Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol (2010) 1.24
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant (2011) 1.23
End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant (2009) 1.22
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol (2008) 1.19
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant (2009) 1.15
Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis (2004) 1.00
Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol Genet Metab (2012) 0.95
Epidemiology of renal dysfunction and patient outcome in atherosclerotic renal artery occlusion. J Am Soc Nephrol (2002) 0.95
A validated disease severity scoring system for Fabry disease. Mol Genet Metab (2009) 0.95
Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol (2009) 0.94
PR interval and the response to enzyme-replacement therapy for Fabry's disease. N Engl J Med (2003) 0.93
Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry. Mol Genet Metab (2011) 0.92
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry. Genet Med (2013) 0.87
Enzyme replacement therapy for Fabry's disease. Lancet (2010) 0.82
Splenomegaly, hypersplenism and peripheral blood cytopaenias in patients with classical Anderson-Fabry disease. Virchows Arch (2008) 0.82
Epidemiology and investigation of acute abdominal presentations in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2007) 0.80
Predictive value of myocardial and coronary imaging in the long-term outcome of potential renal transplant recipients. Int J Cardiol (2009) 0.79
Determinants of renal functional outcome in lupus nephritis: a single centre retrospective study. QJM (2008) 0.78
Milk alkali syndrome associated with excessive ingestion of Rennie: case reports. J Ren Care (2008) 0.75
Impact of a high-dependency care area on the nutritional management of patients with acute uremia. J Ren Nutr (2002) 0.75